Document is current

Article History

Received: 16 October 2023

Accepted: 5 December 2023

First Online: 10 January 2024

Declarations

:

: VS has received research grants to her institution from Abbvie, Biocept, Novartis, Pfizer, Puma Biotechnology, and QUE Oncology, she has been a member of the Novartis Advisory Board since October 2021, and she is the Chair of a Data Safety Monitoring Board with AstraZeneca. She additionally has non-financial support with the Foundation Medicine Study Assays. As noted above, DFH reports receiving grants through his institution from the manufacturers of letrozole (Novartis) and exemestane (Pfizer). DFH reports support unrelated to this study but provided to his institution in the last 24 months during conduct and analysis of this study from AstraZeneca, Menarini Silicon Biosystems, Merrimack Pharmaceuticals, and Pfizer. DFH reports personal income related to consulting or advisory board activities from Arvenis, BioVeca, BioTheranostics a Hologic Company, Cellworks, Centrix, Cepheid, EPIC Sciences, EXACT Sciences, Freenome, Guardant, L-Nutra, Macrogenics, Oncocyte, Predictus BioSciences, Stratipath, Tempus, Turnstone Biologics, and Xilis. The University of Michigan holds a patent for which DFH is the named investigator and which was licensed to Menarini Silicon Biosystems, from whom UM and DFH received annual royalties ending 1/1/2022. DFH reports personally held stock options from InBiomotion, Xilis, and from CellWorks. NLH is a consultant for Myovant Pharmaceuticals, a steering committee member for AstraZeneca, and receives royalties from Up-To-Date. The other authors had no disclosures to report.

: The ELPh study received approval from each of the three participating sites: Indiana University Bren and Melvin Simon Cancer Center, the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, and the University of Michigan Comprehensive Cancer Center.

: Informed consent was obtained from all individuals included in the ELPh study for participation and publication.